文献速递重症综合管理与镇静镇痛复苏、休克与脓毒症

阿片类药物诱导的免疫调节在实验性与临床脓毒症中的评估

Assessment of Opioid-Induced Immunomodulation in Experimental and Clinical Sepsis.
PubMed 文献 · Crit Care Explor · 2023-01-17
一句话结论临床脓毒症中芬太尼暴露与IL-23降低相关且低IL-23与死亡相关,小鼠脓毒症中芬太尼暴露与继发感染后细菌负荷显著升高相关。

本研究分两阶段:临床阶段对一项现有随机对照试验中的脓毒症患者亚组进行事后分析,比较接受芬太尼与未接受阿片类药物的患者;临床前阶段使用C57BL/6小鼠盲肠浆液诱导脓毒症模型,随机接受芬太尼或不用芬太尼,随后进行继发感染。结果显示临床脓毒症中芬太尼暴露者IL-23水平显著降低,低IL-23与死亡相关(p < 0.001),其他细胞因子无显著差异;小鼠脓毒症中芬太尼暴露与继发感染后细菌负荷显著升高相关(p < 0.001),但免疫细胞计数和血浆细胞因子水平基本不受影响。作者认为需进一步研究阿片类药物的免疫调节作用及其意义,尤其在脓毒症后期。

要点

  • 临床脓毒症患者芬太尼暴露与IL-23水平显著降低相关,且低IL-23与死亡相关(p < 0.001)。
  • 临床脓毒症中其他所测细胞因子在芬太尼暴露与未暴露者间无显著差异。
  • 小鼠脓毒症中伴随芬太尼暴露与继发感染后细菌负荷显著升高相关(p < 0.001)。
  • 小鼠脓毒症中芬太尼暴露后免疫细胞计数和血浆细胞因子水平基本不受影响。
  • 作者认为需进一步研究阿片类药物的免疫调节作用及其意义,尤其在脓毒症后期。

适用人群与场景

  • 临床阶段:来自一项现有随机对照试验的脓毒症患者亚组,接受芬太尼者与未接受阿片类药物者比较。
  • 临床前阶段:C57BL/6小鼠盲肠浆液诱导的脓毒症模型,随机接受芬太尼或不用芬太尼,随后进行继发感染。

研究设计与关键结果

  • 研究类型:两阶段临床前与临床研究;临床阶段为对现有随机对照试验中脓毒症患者亚组的事后分析,比较接受芬太尼与未接受阿片类药物者;临床前阶段为小鼠盲肠浆液诱导脓毒症模型,随机接受芬太尼或不用芬太尼,随后进行继发感染。
  • 临床脓毒症中,芬太尼暴露患者IL-23水平显著降低,且低IL-23与死亡相关(p < 0.001)。
  • 临床脓毒症中其他所测细胞因子在芬太尼暴露与未暴露者间无显著差异。
  • 小鼠脓毒症中伴随芬太尼暴露与继发感染后细菌负荷显著升高相关(p < 0.001)。
  • 小鼠脓毒症中芬太尼暴露后免疫细胞计数和血浆细胞因子水平基本不受影响。

证据类型、等级与局限

  • 证据类型:两阶段临床前与临床研究;临床阶段为对现有随机对照试验的事后分析,临床前阶段为小鼠实验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 临床脓毒症中芬太尼暴露与IL-23降低相关且低IL-23与死亡相关,其他细胞因子无显著差异;小鼠脓毒症中芬太尼暴露与继发感染后细菌负荷升高相关,但免疫细胞计数和血浆细胞因子基本不受影响。
  • 作者认为需进一步研究阿片类药物的免疫调节作用及其意义,尤其在脓毒症后期。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

UNLABELLED: Opioids remain a standard supportive therapy in patients admitted to the ICU with sepsis. However, as preclinical models indicate an association between opioid exposure and immunosuppression, the use of this class of drugs warrants investigation. The objective of this study was to investigate whether opioid exposure causes immunosuppression in patients with sepsis, and to use a murine sepsis model to determine the effects of opioid exposure on secondary infection.

HYPOTHESIS: We hypothesized opioid exposure would be associated with immunosuppression in patients with sepsis and secondary infection in a murine sepsis model.

METHODS AND MODELS: This was a two-phase preclinical and clinical study. The clinical phase included a subgroup of patients with sepsis from an existing randomized controlled trial while the preclinical phase used a murine model of sepsis with C57BL/6 mice. In the clinical phase, a post hoc analysis was performed in subjects receiving fentanyl versus no opioid receipt. In the preclinical phase, a murine cecal slurry-induced sepsis model followed by secondary infection was used. Mice were randomized to fentanyl versus no fentanyl concomitantly.

RESULTS: In clinical sepsis, a significant decrease in interleukin-23 (IL-23) level in patients with fentanyl exposure was observed and lower IL-23 was associated with mortality (p < 0.001). Other measured cytokines showed no significant differences. Concomitant fentanyl exposure during murine sepsis was associated with a significantly higher bacterial burden (p < 0.001) after secondary infection; however, immune cell counts and plasma cytokine levels were largely unaffected by fentanyl.

INTERPRETATION AND CONCLUSIONS: Minimal alterations in cytokines were seen with opioid exposure during clinical sepsis. In a preclinical model, opioid exposure during sepsis was associated with ineffective bacterial clearance upon secondary infection. Further studies are warranted to evaluate the immunomodulatory role of opioids and their implications, especially in the post-sepsis period.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. Bissell BD, Sturgill JL, Bruno MEC, et al. Assessment of Opioid-Induced Immunomodulation in Experimental and Clinical Sepsis. Crit Care Explor. 2023. PMID: 36699245. doi:10.1097/CCE.0000000000000849

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。